Cargill Puts Bold Innovation at Center of Effort to Decarbonize Shipping
15.1.2025 08:00:00 CET | Business Wire | Press release
Continued investment in wind assisted propulsion, next-generation fuels and digital solutions key to moving the world’s goods more sustainably
Cargill is advancing a new era in sustainable shipping, putting innovation and collaboration at the core of its mission to move goods responsibly across the globe. Through wind-assisted propulsion technologies, dual-fuel methanol-powered vessels, and digital solutions, Cargill is setting the standard for helping the industry advance progress toward the International Maritime Organization’s (IMO) 2050 net-zero target. Combining technical expertise with a commitment to industry-wide partnerships, Cargill is helping to future-proof the maritime sector while enabling customers to meet their sustainability goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114753261/en/
“Decarbonizing shipping is a monumental task that requires courage, innovation, and collaboration,” said Jan Dieleman, president of Cargill’s Ocean Transportation business. “Our role extends beyond freight-shipping services; we aim to catalyze a shift across the industry toward sustainable practices. Through strategic investments in cutting-edge technology and robust partnerships, we are accelerating the journey to net-zero emissions in shipping.”
Innovating with Wind-Assisted Propulsion: The Pyxis Ocean and Beyond
Leading the charge in wind-assisted propulsion, the Pyxis Ocean—the first dry bulk vessel equipped with BAR Technologies’ WindWings®—completed its maiden voyage in 2023. WindWings are large, rigid sails that harness wind power to reduce fuel use and emissions.
In addition to WindWings, Cargill has expanded its wind-assisted technology program to include VentoFoil vertical suction sails on the NBA Magritte and rotor sails on the TR Lady. With these three vessels the company is experimenting and learning before scaling up technical, operational and commercial aspects. These technologies further utilize wind power to decrease fuel dependency and emissions, aligning with the IMO's target to have 5-10% of maritime energy from renewable sources by 2030.
Cargill believes that wind could make an important contribution to achieving decarbonization goals in the short, medium, and long term. Dieleman says that while the cost of fuels that could contribute to a zero-carbon future may remain high, developing, testing, and improving wind assisted propulsion technologies before these fuels are available could reduce reliance on them.
Transforming Fuels: Biofuels and Methanol-Powered Vessels
Alongside wind propulsion, Cargill is transforming fuel usage across its fleet. The company is pioneering biofuels made from renewable sources, such as fatty acid methyl esters (FAME), providing a drop-in fuel option to lower emissions without extensive engine modifications. In 2023, the company moved from trialing these fuels to frequent execution as it prepares to scale up. Nearly 172,000 metric tons of biofuel blends containing 63,000 metric tons of FAME was lifted in 2023. Cargill is also the first dry-bulk charterer to sign commercial agreements for dual-fuel methanol-powered ships, which are expected to be operational within the next two years. Methanol, a low-carbon alternative fuel, offers a scalable pathway to zero emissions. These methanol-powered vessels—the first of their kind in commercial service—highlight Cargill’s proactive approach in adopting sustainable fuel solutions to support both its own and its customers’ ambitious Scope 3 emissions reduction goals.
Harnessing Digital Solutions for Efficiency and Sustainability
Digital innovation is also central to Cargill ’s decarbonization efforts. Cargill is using advanced digital tools, including voyage optimization technologies, to create digital twins of its vessels. This enables optimal speed and route planning to reduce fuel consumption and emissions. Partnering with ZeroNorth, Cargill leverages these digital solutions to enhance operational efficiency and sustainability, reinforcing its commitment to data-driven progress toward net-zero.
Building a Sustainable Future Through Collaboration
Recognizing that decarbonizing the maritime industry requires a collaborative approach, Cargill partners across the sector to drive meaningful progress. As a founding member of the Maersk Mc-Kinney Moller Center for Zero Carbon Shipping, Cargill works with industry leaders to test and promote alternative fuels, including ammonia and methanol. Cargill is also a key player in the Sea Cargo Charter, a coalition dedicated to reducing shipping’s climate impact through transparency and shared decarbonization frameworks.
“As we continue this journey, we’re focused on solutions that don’t just improve our own operations but drive change across the industry,” added Dieleman. “Our vision is a shipping sector that delivers the goods the world needs while protecting our planet’s future. We’re proud to be part of this transformation and are committed to building a more sustainable future for global shipping.”
For additional information about Cargill’s efforts to decarbonize shipping, visit https://www.cargill.com/transportation/ocean-transportation-sustainability.
About Cargill
Cargill is committed to providing food, ingredients, agricultural solutions, and industrial products to nourish the world in a safe, responsible, and sustainable way. Sitting at the heart of the supply chain, we partner with farmers and customers to source, make and deliver products that are vital for living.
Our 160,000 team members innovate with purpose, providing customers with life’s essentials so businesses can grow, communities prosper, and consumers live well. With 159 years of experience as a family company, we look ahead while remaining true to our values. We put people first. We reach higher. We do the right thing—today and for generations to come. For more information, visit Cargill.com and our News Center.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114753261/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom